Nebivolol Teva (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Teva, is a selective β1‑adrenergic receptor antagonist presented as an oral tablet for oral administration. It is used to reduce high blood pressure and to improve cardiac output in adult patients diagnosed with hypertension or chronic heart failure, offering vasodilatory benefits through nitric oxide release.

GNH USA supplies Nebivolol Teva as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics across global markets with consistent quality and regulatory adherence. All batches are manufactured under GMP conditions and undergo rigorous quality testing before distribution.

Nebivolol is a beta‑blocker indicated for conditions involving elevated cardiovascular workload.

- Hypertension: reduces systolic and diastolic blood pressure, helping patients reach guideline‑recommended targets. - Chronic heart failure: improves left‑ventricular ejection fraction and lowers the risk of hospitalization. - Stable angina: decreases myocardial oxygen demand, relieving chest pain during exertion.

Nebivolol may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Dizziness or light‑headedness: related to blood‑pressure lowering. - Fatigue: a feeling of reduced energy or tiredness. - Nausea: occasional gastrointestinal upset. - Bradycardia: slower than normal heart rate, usually asymptomatic. - Peripheral edema: mild swelling of the lower limbs.

Serious or Rare Side Effects: - Severe bradycardia or heart block: may require medical intervention. - Bronchospasm: especially in patients with underlying asthma or COPD. - Allergic reactions: rash, itching, or anaphylaxis in rare cases. - Hepatic enzyme elevation: abnormal liver function tests. - Acute heart failure decompensation: worsening symptoms in susceptible individuals.

Before initiating Nebivolol, clinicians should consider several safety factors.

- Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Cardiac conduction: avoid in patients with severe bradycardia or advanced AV block. - Respiratory disease: use caution in asthma or chronic obstructive pulmonary disease. - Hepatic impairment: dose adjustment may be needed in severe liver dysfunction. - Concomitant beta‑blockers: avoid combining with other β‑blockers to prevent additive effects. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase nebivolol plasma levels. - Other beta‑blockers: additive negative chronotropic and inotropic effects. - Calcium‑channel blockers that affect AV node (e.g., verapamil, diltiazem): risk of severe bradycardia.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypotensive response. - ACE inhibitors or ARBs: monitor for excessive blood‑pressure reduction. - NSAIDs: can blunt antihypertensive effect. - Antidiabetic agents: nebivolol may mask hypoglycaemia symptoms. - Antiarrhythmic drugs: watch for conduction abnormalities.